ID: ALA4162139

Max Phase: Preclinical

Molecular Formula: C26H32N2O3

Molecular Weight: 420.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCOc1ccc(-c2cc(OCCN3CCCCC3)c3cc(OC)ccc3n2)cc1

Standard InChI:  InChI=1S/C26H32N2O3/c1-3-16-30-21-9-7-20(8-10-21)25-19-26(31-17-15-28-13-5-4-6-14-28)23-18-22(29-2)11-12-24(23)27-25/h7-12,18-19H,3-6,13-17H2,1-2H3

Standard InChI Key:  KMFGCJWPFAWJQJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 420.55

Molecular Weight (Monoisotopic): 420.2413

AlogP: 5.56

#Rotatable Bonds: 9

Polar Surface Area: 43.82

Molecular Species: BASE

HBA: 5

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.03

CX LogP: 5.44

CX LogD: 3.81

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.45

Np Likeness Score: -1.01

References

1. Felicetti T, Cannalire R, Pietrella D, Latacz G, Lubelska A, Manfroni G, Barreca ML, Massari S, Tabarrini O, Kieć-Kononowicz K, Schindler BD, Kaatz GW, Cecchetti V, Sabatini S..  (2018)  2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.,  61  (17): [PMID:30067360] [10.1021/acs.jmedchem.8b00791]

2. Felicetti T, Cedraro N, Astolfi A, Cernicchi G, Mangiaterra G, Vaiasicca S, Massari S, Manfroni G, Barreca ML, Tabarrini O, Biavasco F, Cecchetti V, Vignaroli C, Sabatini S..  (2022)  New C-6 functionalized quinoline NorA inhibitors strongly synergize with ciprofloxacin against planktonic and biofilm growing resistant Staphylococcus aureus strains.,  241  [PMID:35963131] [10.1016/j.ejmech.2022.114656]

Source

Source(1):

• Scientific Literature